(Q35201049)

7 August 2017

1 reference

title

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models (English)

1 reference

7 August 2017

1

Jerome J Schentag

1 reference

7 August 2017

Alison K Meagher

2

1 reference

PubMed ID

12921513

7 August 2017

Alan Forrest

series ordinal

3

1 reference

PubMed ID

12921513

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Annals of Pharmacotherapy

7 August 2017

1 reference

7 August 2017

37

1 reference

7 August 2017

9

1 reference

7 August 2017

1287-1298

1 reference

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

7 August 2017

1 reference

AUIC--a general target for the optimization of dosing regimens of antibiotics?

21 January 2018

1 reference

What have we learned from pharmacokinetic and pharmacodynamic theories?

21 January 2018

1 reference

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

Animal model pharmacokinetics and pharmacodynamics: a critical review

21 January 2018

1 reference

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar

21 January 2018

1 reference

Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

21 January 2018

1 reference

Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic model

21 January 2018

1 reference

AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin

21 January 2018

1 reference

Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model

21 January 2018

1 reference

The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses

21 January 2018

1 reference

Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships

21 January 2018

1 reference

Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model.

21 January 2018

1 reference

Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio

21 January 2018

1 reference

Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae

21 January 2018

1 reference

Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones

21 January 2018

1 reference

Quinolone Resistance: Older Concepts and Newer Developments

21 January 2018

1 reference

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance

21 January 2018

1 reference

Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae

21 January 2018

1 reference

Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae

21 January 2018

1 reference

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

21 January 2018

1 reference

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States

21 January 2018

1 reference

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

21 January 2018

1 reference

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

21 January 2018

1 reference

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

Levofloxacin failure in a patient with pneumococcal pneumonia

21 January 2018

1 reference

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis

21 January 2018

1 reference

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

21 January 2018

1 reference

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

21 January 2018

1 reference

Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime

21 January 2018

1 reference

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

21 January 2018

1 reference

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

21 January 2018

1 reference

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy

21 January 2018

1 reference

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae

21 January 2018

1 reference

Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model

21 January 2018

1 reference

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

21 January 2018

1 reference

The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy

21 January 2018

1 reference

Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model

21 January 2018

1 reference

Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection

21 January 2018

1 reference

Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models

21 January 2018

1 reference

Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.

21 January 2018

1 reference

Effect of protein binding on cefmenoxime steady-state kinetics in critical patients

21 January 2018

1 reference

The future of fluoroquinolones

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1C199

1 reference

7 August 2017

1 reference

PubMed ID

12921513